🔎 Trials Near Me

Home › Scleroderma › Maryland › Baltimore

Scleroderma clinical trials in Baltimore, MD

6 studies for Scleroderma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

RecruitingPhase 2
  • Johns Hopkins Asthma and Allergy Center, Baltimore
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06655155

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RecruitingPhase 1
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

RecruitingPhase 3
  • Johns Hopkins Hospital, Baltimore
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07497087

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

RecruitingPhase 1
  • Johns Hopkins Hospital, Baltimore
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

RecruitingPhase 2/3
  • GSK Investigational Site, Baltimore
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

RecruitingPhase 2
  • Johns Hopkins University School of Medicine, Baltimore
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072

About Scleroderma

Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.

More about Scleroderma on MedlinePlus

Scleroderma trials in other cities

Other studies in Baltimore

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.